Cencora Shares Surge 4.71% on Strategic Pharma Partnership as $290M Volume Ranks 361st in U.S. Turnover

. 23, 2025, , ranking 361st among U.S. equities by daily turnover. The move followed a strategic update disclosing a multi-year partnership with a leading pharmaceutical distributor, which analysts noted could expand its market share in specialty pharmacy services. Additionally, the company announced the completion of a cost-optimization initiative, .

Market participants highlighted the stock's volume surge as a key driver, with institutional buying activity detected in post-market data. The partnership announcement specifically drew attention for its potential to streamline supply chain operations, a critical factor in the healthcare distribution sector. Short-term traders observed improved liquidity conditions, .

To perform this back-test I need to clarify a couple of practical details so that the test matches your intention and fits within the capabilities of our back-testing engine: 1. Market universe • Should we limit the universe to U.S.-listed common stocks (NASDAQ + NYSE), or do you have another market/universe in mind? 2. Execution price • Do you want to (a) buy at the day’s close and sell at the next day’s close, or (b) buy at the next day’s open and sell at that day’s close? (Most volume-based studies use close-to-close for simplicity, but please confirm.) 3. Rebalancing costs • Should we ignore transaction costs/slippage, or apply a fixed bid-ask spread or commission assumption? Once I have this information I’ll generate the trading signals (top-500 by volume each day), run the back-test from 2022-01-01 to today, and present the performance report.